Company
Allogene Therapeutics
Our mission is to create and lead the next revolution in cell therapy by delivering to patients the first allogeneic CAR T cell (AlloCAR T) products for blood cancers, solid tumors and autoimmune disease.
Also known as Allogene Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Allogene Therapeutics, Inc.
- allogene.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease.
Funding snapshot
- Total raised
- $412MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $412M2018-04-06
Funding rounds
- Round, 2018
- $412M2018-04-06, SEC form D sold, 23 investors
Loading relationship preview